Background
Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Although the cure rate for this disease is greater than 85%, ALL remains a primary cause of cancer-related deaths in children due to relapse of disease. Importantly, there has been little progress in improving outcomes for patients with relapsed or refractory disease.